重组人干扰素α2b不同剂量雾化吸入应用于儿童病毒性肺炎的效果对比分析
|
摘要
目的:对比分析病毒性肺炎患儿雾化吸入不同剂量重组人干扰素α2b的临床效果。方法:随机数字表法将2017年2月至2018年8月我科收治的93例病毒性肺炎患儿分为2组,20万U·kg~(-1)组47例予20万U·kg~(-1)/次重组人干扰组α2b雾化吸入,10万U·kg~(-1)组46例予重组人干扰素α2b每次10万U·kg~(-1)雾化吸入,治疗3 w,对比两组治疗总有效率及气促、啰音、咳嗽、发热等症状消失时间和住院时间,并使用酶联免疫吸附法检测两组患儿白细胞介素-6(Interleukin-6,IL-6)、C反应蛋白(C-reactive protein,CRP)及肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)等炎性因子治疗前后变化情况及安全性。结果:20万U·kg~(-1)组患儿住院、气促、啰音及咳嗽消失时间和退热时间均少于10万U·kg~(-1)组(P<0.05),3 w末20万U·kg~(-1)组患儿血清CRP、IL-6及TNF-α水平均低于10万U·kg~(-1)组(P<0.05),两组总有效率及不良反应情况无统计学意义(P>0.05)。结论:病毒性肺炎患儿雾化吸入重组人干扰素α2b可显著改善其炎症状态及咳嗽、气促等体征,其中每次20万U·kg~(-1)用量较10万U·kg~(-1)更有效且较安全。
Objective: To compare the effects of aerosolized different doses of recombinant human interferon α2b in children with viral pneumonia. Methods: Randomized digital table method was used to divide 93 children with viral pneumonia admitted to our department from February 2017 to August 2018 into two groups. In the 200,000 U·kg~(-1) group(n=47) received inhalation of 200,000 U·kg~(-1) recombinant human interference group α2b. The 100,000 U·kg~(-1) group(n=46) received 100,000 U·kg~(-1) for 3 weeks. The time of disappearance of symptoms such as shortness of breath, voice, cough, fever, and hospitalization time was compared. The expression of interleukin-6(IL-6), C-reactive protein(CRP), tumor necrosis factor-α(Tumor necrosis factor-α, TNF-α) and other inflammatory factors before and after treatment was detected by enzyme-linked immunosorbent assay. Results: The disappearance time and fever time of hospitalization, shortness of breath, voice and cough were lower of the 200,000 U·kg~(-1) group than that of the 100,000 U·kg~(-1) group. The levels of CRP, IL-6 and TNF-α of the 200,000 U·kg~(-1) group was significantly lower than those of 100,000 U·kg~(-1 )group(P<0.05). The total effective rate and adverse reactions of the two groups were not statistically significant(P>0.05). Conclusion: Inhalation of recombinant human interferon α2b in children with viral pneumonia can significantly improve the inflammation and signs of cough and shortness of breath, while the amount of 200,000 U·kg~(-1) is more effective than 100,000 U·kg~(-1).
Objective: To compare the effects of aerosolized different doses of recombinant human interferon α2b in children with viral pneumonia. Methods: Randomized digital table method was used to divide 93 children with viral pneumonia admitted to our department from February 2017 to August 2018 into two groups. In the 200,000 U·kg~(-1) group(n=47) received inhalation of 200,000 U·kg~(-1) recombinant human interference group α2b. The 100,000 U·kg~(-1) group(n=46) received 100,000 U·kg~(-1) for 3 weeks. The time of disappearance of symptoms such as shortness of breath, voice, cough, fever, and hospitalization time was compared. The expression of interleukin-6(IL-6), C-reactive protein(CRP), tumor necrosis factor-α(Tumor necrosis factor-α, TNF-α) and other inflammatory factors before and after treatment was detected by enzyme-linked immunosorbent assay. Results: The disappearance time and fever time of hospitalization, shortness of breath, voice and cough were lower of the 200,000 U·kg~(-1) group than that of the 100,000 U·kg~(-1) group. The levels of CRP, IL-6 and TNF-α of the 200,000 U·kg~(-1) group was significantly lower than those of 100,000 U·kg~(-1 )group(P<0.05). The total effective rate and adverse reactions of the two groups were not statistically significant(P>0.05). Conclusion: Inhalation of recombinant human interferon α2b in children with viral pneumonia can significantly improve the inflammation and signs of cough and shortness of breath, while the amount of 200,000 U·kg~(-1) is more effective than 100,000 U·kg~(-1).
引文
1 秦鹏飞,刘书娟,韩龙,等.小儿病毒性肺炎的中医药治疗进展[J].中成药,2017,39(4):800-803.
2 梁陵.丹参粉针佐治小儿病毒性肺炎疗效观察[J].安徽中医药大学学报,2016,35(3):43-45.
3 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655.
4 张茂好.降钙素原检测在小儿细菌性肺炎早期诊断中的意义[J].中国感染控制杂志,2016,15(10):800-801.
5 黄扬.不同剂量重组人干扰素α 2b雾化吸入治疗毛细支气管炎临床研究[J].中国现代医生,2018,56(34):107-109.
6 肖婧,应晶.不同剂量重组人干扰素-α1b治疗小儿病毒性肺炎的疗效及对其炎症因子、肺功能指标的影响[J].中国妇幼保健,2019,34(01):94-97.
7 黎小年.不同剂量重组人干扰素α2b注射液对小儿病毒性肺炎的疗效研究[J].医学与哲学(B),2018,39(05):27-29.
8 贺晓红,张薇,薛梅,等.不同剂量重组人干扰素α2b雾化吸入治疗儿童病毒性肺炎的疗效及其对血清炎性因子和免疫功能的影响[J].儿科药学杂志,2018,24(10):25-29.
2 梁陵.丹参粉针佐治小儿病毒性肺炎疗效观察[J].安徽中医药大学学报,2016,35(3):43-45.
3 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655.
4 张茂好.降钙素原检测在小儿细菌性肺炎早期诊断中的意义[J].中国感染控制杂志,2016,15(10):800-801.
5 黄扬.不同剂量重组人干扰素α 2b雾化吸入治疗毛细支气管炎临床研究[J].中国现代医生,2018,56(34):107-109.
6 肖婧,应晶.不同剂量重组人干扰素-α1b治疗小儿病毒性肺炎的疗效及对其炎症因子、肺功能指标的影响[J].中国妇幼保健,2019,34(01):94-97.
7 黎小年.不同剂量重组人干扰素α2b注射液对小儿病毒性肺炎的疗效研究[J].医学与哲学(B),2018,39(05):27-29.
8 贺晓红,张薇,薛梅,等.不同剂量重组人干扰素α2b雾化吸入治疗儿童病毒性肺炎的疗效及其对血清炎性因子和免疫功能的影响[J].儿科药学杂志,2018,24(10):25-29.